期刊文献+

缬沙坦中2-氰基-4’-溴甲基联苯和2-氰基-4’,4’-二溴甲基联苯的高效液相色谱法测定方法的建立及评价

Establishment and Evaluation of HPLC Method for the Determination of 2-cyano-4 ’-Bromomethylbiphenyl and 2-cyano-4’, 4 ’-Dibromomethylbiphenyl in Valsartan
原文传递
导出
摘要 目的建立缬沙坦中2-氰基-4’-溴甲基联苯(杂质Ⅰ)和2-氰基-4’,4’-二溴甲基联苯(杂质Ⅱ)的高效液相色谱法(HPLC)测定方法。方法采用HPLC,C18色谱柱(推荐使用ACE EXCEL 3 C18-AR,150×46 mm),流动相为乙腈:0.1%乙酸溶液(52:48),检测波长为260nm,柱温为40℃,流速为1.0ml/min,进样量为20μl。结果杂质Ⅰ与缬沙坦和杂质Ⅱ的分离度符合要求。杂质Ⅰ和杂质Ⅱ浓度在10~500 ng/ml的范围内线性良好,杂质Ⅰ和杂质Ⅱ检测限为5 ng/ml,定量限为10 ng/ml,精密度、重复性、准确度(加样回收率)、耐用性符合要求。样品溶液室温放置和光照后稳定,对照品溶液需4℃放置。结论该方法简单、准确、重现性好、耐用性好,可用于控制缬沙坦中杂质Ⅰ、杂质Ⅱ含量。 Objective To establish a HPLC method to test content of 2-cyano 4 ’-bromine-biphenyl(impurity Ⅰ) and 2 – cyano-4’, 4 ’-dibromomethyl-biphenyl(impurityⅡ) of valsartan. Methods HPLC, C18 column was used.(ACE EXCEL 3 c18-ar, 150×46 mm is recommended to use) with the mobile phase of acetonitrile-0.1% acetic acid solution(52:48) at a flow rate of 1.0 m L/min, with the detection wavelength at 260 nm, the column temperature of 40 ℃ and the injection volume of 20 μL. Results The degree of separation of Impurity Ⅰ with valsartan and impurityⅡ conformed to requirements. The concentration for Impurity Ⅰand impurityⅡ were in the range of 10-500 ng·m L-1. The detection limit of impurityⅠand impurity Ⅱ was 5 ng/ml, quantitative limit was 10 ng/ml. Furthermore, the precision, repeatability, accuracy(sample recovery rate) and durability meet the requirements. The sample solution was stable under room temperature and light, and the control solution needed to be placed at 4 ℃. Conclusion The method is simple, accurate, reproducible and durable. It can be used to control the concentration of impurity I and II in valsartan.
作者 张岩琛 余洁 刘晓强 朱菁华 ZHANG Yan-Chen;YU Jie;LIU Xiao-Qiang;ZHU Jing-Hua(Changzhou Food and Drug Supervision and Inspection Center,Changzhou 213002,China)
出处 《中国药物经济学》 2020年第10期28-33,共6页 China Journal of Pharmaceutical Economics
关键词 缬沙坦 2-氰基-4’-溴甲基联苯 2-氰基-4’ 4’-二溴甲基联苯 高效液相色谱法 Valsartan 2-cyano-4’-bromo-methyl-biphenyl 2-cyano-4’ 4’-dibromomethyl-biphenyl HPLC
  • 相关文献

参考文献3

二级参考文献41

  • 1张玉风.缬沙坦与卡托普利治疗高血压疗效对比[J].求医问药(下半月),2013(2):435-435. 被引量:4
  • 2王东方,李永峰,程学华.缬沙坦治疗扩张型心肌病心力衰竭的疗效观察[J].河北医科大学学报,2005,26(2):89-90. 被引量:2
  • 3雷华,邹桂和.缬沙坦治疗心力衰竭的疗效和安全性分析[J].国际医药卫生导报,2005,11(16):86-87. 被引量:2
  • 4翟桂兰,祝焕林,王庆茹,赵凤琴.缬沙坦对心力衰竭患者心室重构的影响[J].心脏杂志,2005,17(6):567-569. 被引量:9
  • 5中国高血压防治指南修订委员会.中国高血压防治指南[S].第3版.2010-03-11.
  • 6Lapu-Bula R, Ofili E. From hypertension to heart failure: role of ni- trie oxide-mediated endothelial dysfunction and emerging insights from myocardial contrast echoeardiography [ J ]. Am J C.ardiol, 2007,99 (6) :7-14.
  • 7Kostis JB. From hypertension to heart failure: update on the manage- ment of systolic and diastolic dysfunction[ J ]. Am J tlyperten~s,2003, 16(9) :18-21.
  • 8Prabowo P, Arwanto A, Soemantri D. A comparison of valsartan and eaptopril in patients with essential hypertension in Indonesia[ J]. In- ternational Journal of Clinical Practice, 1999,53 (4) :268-272.
  • 9白风桐,白风新.缬沙坦逆转原发性高血压左心室肥厚的临床观察[J].中国医药指南,2010,8(14):274-275.
  • 10谢琼瑛.缬沙坦治疗原发性高血压89例临床疗效观察[J].中国健康月刊,2011,30(9):63-64.

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部